Case number 1:22-cv-01461
Amicus Therapeutics US, LLC et al v. Teva Pharmaceuticals USA, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 3, 2025 | 230 | ANSWERING BRIEF in Opposition re 223 MOTION for Summary Judgment of Invalidity of All Asserted Patents Under 35 U.S.C. § 101 filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..Reply Brief due date per Local Rules is 7/10/2025. (Jacobs, Karen) (Entered: 07/03/2025) (25) |
| Jul 3, 2025 | 231 | STATEMENT - Amicus's Response to Aurobindo's Statement of Material Facts and Amicus's Concise Statement of Material Facts That Aurobindo's Summary Judgment Motion Ignores by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Jacobs, Karen) (Entered: 07/03/2025) (7) |
| Jul 3, 2025 | 232 | DECLARATION of Aileen Huang in Support of Amicus's Answering Brief in Opposition to Aurobindo's Motion for Summary Judgment of Invalidity Under 35 U.S.C. § 101 re 230 Answering Brief in Opposition, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F)(Jacobs, Karen) (Entered: 07/03/2025) (0) |
| Jul 3, 2025 | 233 | [SEALED] EXHIBIT re 232 Declaration, Exhibit A to Declaration of Aileen Huang by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Jacobs, Karen) (Entered: 07/03/2025) (0) |
| Jun 23, 2025 | 228 | REDACTED VERSION of 225 Exhibit to a Document [SEALED] EXHIBIT re 224 Declaration, Exhibit 6 by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Attachments: # 1 Exhibit 7, # 2 Exhibit 8, # 3 Exhibit 9)(Myer, R.) (Entered: 06/23/2025) (0) |
| Jun 23, 2025 | 229 | REDACTED VERSION of 226 Opening Brief in Support, re 223 MOTION for Summary Judgment of Invalidity of All Asserted Patents Under 35 U.S.C. 101 by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 06/23/2025) (19) |
| Jun 19, 2025 | 227 | NOTICE to Take Deposition of John L. Jefferies, M.D. on June 26, 2025 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 06/19/2025) (2) |
| Jun 12, 2025 | 223 | MOTION for Summary Judgment of Invalidity of All Asserted Patents Under 35 U.S.C. § 101 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certificate of Service)(Myer, R.) (Entered: 06/12/2025) (0) |
| Jun 12, 2025 | 224 | DECLARATION of George J. Barry, III in Support of Defendants Motion for Summary Judgment re 223 MOTION for Summary Judgment of Invalidity of All Asserted Patents Under 35 U.S.C. § 101 by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Attachments: # 1 Exhibit 1A, # 2 Exhibit 1B, # 3 Exhibit 1C, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 10)(Myer, R.) (Entered: 06/12/2025) (0) |
| Jun 12, 2025 | 225 | [SEALED] EXHIBIT re 224 Declaration, Exhibit 6 by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Attachments: # 1 Exhibit 7, # 2 Exhibit 8, # 3 Exhibit 9)(Myer, R.) (Entered: 06/12/2025) (0) |
| Jun 12, 2025 | 226 | [SEALED] OPENING BRIEF in Support re 223 MOTION for Summary Judgment of Invalidity of All Asserted Patents Under 35 U.S.C. § 101 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..Answering Brief/Response due date per Local Rules is 6/26/2025. (Myer, R.) (Entered: 06/12/2025) (0) |
| Jun 10, 2025 | 222 | NOTICE to Take Deposition of Dr. Jeffrey A. Medin on June 13, 2025 filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Clark, Cameron) (Entered: 06/10/2025) (3) |
| Jun 4, 2025 | 221 | NOTICE to Take Deposition of Robert J. Hopkin, M.D. on June 10, 2025 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 06/04/2025) (2) |
| May 26, 2025 | 220 | NOTICE to Take Deposition of John L. Jefferies, M.D. on May 29, 2025 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 05/26/2025) (2) |
| May 14, 2025 | 219 | STIPULATION and [Proposed] Order Regarding Expert Depositions by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Clark, Cameron) (Entered: 05/14/2025) (2) |
| May 2, 2025 | 218 | NOTICE OF SERVICE of Defendants' Rebuttal Expert Report of Dr. Jeffrey A. Medin on Secondary Considerations of Non- Obviousness and Supporting Exhibit A filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 05/02/2025) (3) |
| Apr 7, 2025 | 216 | NOTICE OF SERVICE of Defendants' Opening Expert Report of Dr. Jeffrey A. Medin on Patent Invalidity and Supporting Exhibits A-C filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 04/07/2025) (3) |
| Apr 7, 2025 | 217 | NOTICE OF SERVICE of Opening Report of John L. Jefferies, M.D. filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Jacobs, Karen) (Entered: 04/07/2025) (3) |
| Apr 1, 2025 | 215 | NOTICE OF SERVICE of Plaintiffs' Fourth Supplemental Objections and Responses to Interrogatory No. 7 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Jacobs, Karen) (Entered: 04/01/2025) (3) |
| Mar 16, 2025 | 214 | NOTICE OF SERVICE of Plaintiffs' Supplemental Objections and Responses to Interrogatory No. 4 filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Jacobs, Karen) (Entered: 03/16/2025) (3) |
| Mar 13, 2025 | 213 | STIPULATION TO EXTEND TIME for Expert Report Deadlines to dates as prescribed in Proposed Order - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 03/13/2025) (3) |
| Feb 27, 2025 | 212 | NOTICE OF SERVICE of Defendants' Supplemental Invalidity Contentions and supporting Appendix AA-DD filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 02/27/2025) (3) |
| Feb 21, 2025 | 210 | NOTICE OF SERVICE of Plaintiff's Supplemental Responses to Interrogatory Nos. 3-5, 7, 8, 10, 12 & 18 filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Jacobs, Karen) (Entered: 02/21/2025) (3) |
| Feb 21, 2025 | 211 | NOTICE OF SERVICE of Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Second Supplemental Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 13-14) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Main Document 211 replaced on 2/24/2025) (sam). (Entered: 02/21/2025) (3) |
| Feb 13, 2025 | 207 | NOTICE OF SERVICE of Plaintiff's Second Supplemental Response to Interrogatory No. 11 filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Clark, Cameron) (Entered: 02/13/2025) (3) |
| Feb 13, 2025 | 208 | NOTICE to Take Deposition of Michael Keavany on February 17, 2025 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 02/13/2025) (2) |
| Feb 13, 2025 | 209 | NOTICE to Take Deposition of Jeff Castelli on February 21, 2025 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 02/13/2025) (2) |
| Feb 10, 2025 | 206 | Amended ANSWER to Complaint originally filed in Civil Action No.1:24-cv-01331 by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Attachments: # 1 Redline Amended Answer)(Myer, R.) (Entered: 02/10/2025) (0) |
| Feb 8, 2025 | 204 | NOTICE to Take Deposition of Rohit Ghan, Ph.D. on February 18, 2025 filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Dellinger, Megan) (Entered: 02/08/2025) (3) |
| Feb 8, 2025 | 205 | NOTICE to Take Deposition of Michael Keavany on February 12, 2025 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 02/08/2025) (2) |
| Feb 6, 2025 | 203 | ANSWER to Complaint originally filed in Civil Action No.1:24-cv-01331 by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 02/06/2025) (30) |
| Feb 4, 2025 | 202 | ORAL ORDER: The Court, having reviewed Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.’s (“Aurobindo”) January 27, 2025 letter, (D.I. 198 ), appreciates Aurobindo’s explanation as to why the proposed filing of a Section 101-related summary judgment motion could promote efficiency here. In light of the representations that Aurobindo makes in its letter, and in light of the fact that Plaintiffs do not oppose the filing of such a motion, (id. at 1 n.1), the Court hereby GRANTS Aurobindo’s request and ORDERS as follows: (1) The proposed briefing schedule for such a motion set out in the letter, (id. at 2), is SO ORDERED.; and (2) Aurobindo’s opening brief and Plaintiffs’ answering brief shall not exceed twenty (20) double-spaced pages, respectively. Aurobindo’s reply brief shall not exceed ten (10) double-spaced pages. Ordered by Judge Christopher J. Burke on 02/04/2025. (smg) (Entered: 02/04/2025) (0) |
| Feb 3, 2025 | 201 | NOTICE to Take Deposition of Elfrida Benjamin on February 6, 2025 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 02/03/2025) (2) |
| Jan 31, 2025 | 199 | MOTION for Pro Hac Vice Appearance of Attorney Aileen Huang - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Clark, Cameron) (Entered: 01/31/2025) (5) |
| Jan 31, 2025 | 200 | Pro Hac Vice Fee - Credit Card Payment received for Aileen Huang. ( re 199 MOTION for Pro Hac Vice Appearance of Attorney Aileen Huang )( Payment of $ 50, receipt number ADEDC-4605297).(Clark, Cameron) (Entered: 01/31/2025) (0) |
| Jan 27, 2025 | 198 | Letter to The Honorable Christopher J. Burke from R Touhey Myer regarding Summary Judgment - re 194 Oral Order. (Myer, R.) Modified on 1/28/2025 (smg). (Entered: 01/27/2025) (3) |
| Jan 23, 2025 | 197 | NOTICE of Withdrawal and Substitution of Counsel by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. (Jacobs, Karen) (Entered: 01/23/2025) (1) |
| Jan 21, 2025 | 195 | STIPULATION and [Proposed] Order to Amend Scheduling Order re 194 Oral Order,,, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 01/21/2025) (5) |
| Jan 21, 2025 | 196 | SO ORDERED, D.I. 195 Stipulation and Order to Amend Scheduling Order filed by Amicus Therapeutics, Inc., Amicus Therapeutics US, LLC. (Fact Discovery completed by 2/21/2025, Opening Expert Reports due by 3/27/2025, Rebuttal Expert Reports due by 4/24/2025, Expert Discovery due by 6/5/2025, Proposed Pretrial Order due by 8/15/2025, A Pretrial Conference is set for 9/19/2025 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke, A 5-day Bench Trial is set for 9/29/2025 at 09:00 AM in Courtroom 2A before Judge Christopher J. Burke. See Stipulation for further details and deadlines.) Signed by Judge Christopher J. Burke on 01/21/2025. (smg) (Entered: 01/21/2025) (5) |
| Jan 15, 2025 | 194 | ORAL ORDER: The Court, having reviewed the parties’ Stipulation to Amend the Scheduling Order, (D.I. 189 ), hereby ORDERS that the parties shall submit a proposed Scheduling Order by no later than January 21, 2025 that includes a 5-day bench trial to begin on September 29, 2025 at 9:00 a.m. and a pretrial conference set for September 19, 2025 at 11:00 a.m., all in Courtroom 2A before Judge Christopher J. Burke. The Court notes that, at this time, it is not inclined to permit the filing of summary judgment motions on Section 101, and so the proposed Scheduling Order shall not include dates relating thereto. That said, to the extent that the parties believe it would serve efficiency for such a summary judgment motion to be filed in the case, by January 27, 2025, they may file a letter with the Court not to exceed two (2) single-spaced pages explaining why that is so. Ordered by Judge Christopher J. Burke on 01/15/2025. (smg) (Entered: 01/15/2025) (0) |
| Jan 9, 2025 | 193 | NOTICE OF SERVICE of Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Final Election of Asserted Prior Art Pertaining to Asserted Claims of U.S. Patent Nos. 11,833,164; 12,042,489; and 12,042,490 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 01/09/2025) (3) |
| Jan 8, 2025 | 192 | ORDER in case 1:22-cv-01461-CJB; granting (10) Motion to Consolidate Cases in case 1:24-cv-01331-CFC. Signed by Judge Colm F. Connolly on 1/8/2025. Associated Cases: 1:24-cv-01331-CFC, 1:22-cv-01461-CJB (mws) (Entered: 01/08/2025) (2) |
| Jan 7, 2025 | 189 | STIPULATION to Amend Scheduling Order re 183 SO ORDERED,, Set Deadlines/Hearings,, Terminate Deadlines and Hearings, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 01/07/2025) (5) |
| Jan 7, 2025 | 190 | STIPULATION and Covenant Not to Sue Regarding U.S. Patent No. 12,109,205 by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 01/07/2025) (2) |
| Jan 7, 2025 | 191 | STIPULATION and Order to Narrow the Remaining Issues Between Plaintiffs and Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 01/07/2025) (4) |
| Jan 2, 2025 | 188 | NOTICE of Change of Firm Affiliation of Certain Pro Hac Vice Counsel by Lupin Ltd., Lupin Pharmaceuticals, Inc. (Phillips, John) (Entered: 01/02/2025) (3) |
| Dec 12, 2024 | 187 | NOTICE OF SERVICE of Final Election of Asserted Prior Art filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 12/12/2024) (3) |
| Dec 6, 2024 | 186 | NOTICE OF SERVICE of Plaintiffs' Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 12/06/2024) (3) |
| Oct 24, 2024 | 185 | CONSENT JUDGMENT and PERMANENT INJUNCTION as to Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (See Consent Judgment for further details.) Signed by Judge Christopher J. Burke on 10/24/2024. (smg) (Entered: 10/24/2024) (4) |
| Oct 17, 2024 | 184 | STIPULATION for Entry of Consent Judgment and Permanent Injunction as to Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Attachments: # 1 Proposed Consent Judgment and Permanent Injunction)(Stover, Chad) (Entered: 10/17/2024) (0) |
| Oct 3, 2024 | 183 | ORDER GRANTING D.I. 182 Stipulation to Amend Scheduling Order filed by Amicus Therapeutics, Inc., Amicus Therapeutics US, LLC. (A Pretrial Conference is set for 7/25/2025 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke. A 5-day Bench Trial is set for 8/4/2025 at 09:00 AM in Courtroom 2A before Judge Christopher J. Burke.) (See Order for further details and deadlines.) Signed by Judge Christopher J. Burke on 10/3/2024. (smg) (Entered: 10/03/2024) (3) |
| Sep 26, 2024 | 182 | STIPULATION to Amend Scheduling Order re 176 Stipulation, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 09/26/2024) (3) |
| Sep 19, 2024 | 181 | STIPULATION TO EXTEND TIME to Provide the Court with Pretrial Conference and Trial Dates to September 26, 2024 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 09/19/2024) (2) |
| Sep 12, 2024 | 180 | NOTICE OF SERVICE of (1) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-11); (2) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs Fourth Set of Interrogatories (Nos. 15-17); and (3) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 09/12/2024) (3) |
| Sep 11, 2024 | 179 | NOTICE OF SERVICE of Plaintiffs' Supplemental Responses to Interrogatory Nos. 7 & 16 filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 09/11/2024) (3) |
| Sep 10, 2024 | 178 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Fed. R. Civ. P. 30(B)(6) Notice of Deposition filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 09/10/2024) (3) |
| Sep 5, 2024 | 176 | STIPULATION and [Proposed] Order to Amend Scheduling Order re SO ORDERED, SO ORDERED, 25 Proposed Order, SO ORDERED,, Set Scheduling Order Deadlines, 137 SO ORDERED,,,, Set/Reset Scheduling Order Deadlines,,, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 09/05/2024) (3) |
| Sep 5, 2024 | 177 | NOTICE OF SERVICE of 1) Plaintiffs' Response to Defendants' Third Set of Joint Requests for Production (Nos. 91-96) and 2) Plaintiffs' Responses and Objections to Defendants' Third Set of Interrogatories (Nos. 17-18) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 09/05/2024) (3) |
| Sep 4, 2024 | 175 | NOTICE OF SERVICE of 1. Teva's Responses and Objections to Plaintiff's First Set of Requests for Admission (Nos. 1 - 11) 2. Teva's Responses and Objections to Plaintiffs' Notice of Deposition 3. Teva's Responses and Objections to Plaintiffs' Fourth Set of Interrogatories (Nos. 15 - 17) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 09/04/2024) (3) |
| Aug 29, 2024 | 174 | NOTICE OF SERVICE of Subpoena to Produce Documents, Information, or Objects, or to Permit Inspection of Premises in a Civil Action on UCLA Health System filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 08/29/2024) (30) |
| Aug 27, 2024 | 172 | MOTION for Pro Hac Vice Appearance of Attorney Noorossadat Torabi - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Keller, Karen) (Entered: 08/27/2024) (4) |
| Aug 27, 2024 | 173 | Pro Hac Vice Fee - Credit Card Payment received for Noorossadat Torabi. ( re 172 MOTION for Pro Hac Vice Appearance of Attorney Noorossadat Torabi )( Payment of $ 50, receipt number ADEDC-4485846).(Keller, Karen) (Entered: 08/27/2024) (0) |
| Aug 22, 2024 | 171 | NOTICE OF SERVICE of 1) Plaintiffs' Final Election of Asserted Claims (directed to Teva) and 2) Plaintiffs' Final Election of Asserted Claims (directed to all defendants) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 08/22/2024) (3) |
| Aug 9, 2024 | 170 | STIPULATION TO EXTEND TIME for Plaintiffs to serve a final election of asserted claims and for Defendants to serve a final election of asserted prior art to August 22, 2024 for Plaintiffs and September 5, 2024 for Defendants - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 08/09/2024) (2) |
| Aug 8, 2024 | 166 | NOTICE OF SERVICE of Defendants' Notice of Deposition to Plaintiffs, Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc., Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 08/08/2024) (3) |
| Aug 8, 2024 | 167 | ANSWER to 155 Answer to Amended Complaint, Counterclaim by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 08/08/2024) (30) |
| Aug 8, 2024 | 168 | ANSWER to Complaint // Answer to Defendants' Counterclaims [D.I. 16 in 24-696-CFC case] by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 08/08/2024) (12) |
| Aug 8, 2024 | 169 | NOTICE OF SERVICE of Defendants' Second Supplemental Preliminary Disclosure of Prior Art filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 08/08/2024) (3) |
| Aug 7, 2024 | 165 | NOTICE OF SERVICE of 1) Defendants' Third Set of Interrogatories (nos. 17-18); 2) Defendants' Third Set of Joint Requests for Production to Plaintiffs (nos. 91-96) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 08/07/2024) (2) |
| Aug 5, 2024 | 163 | NOTICE OF SERVICE of (1) Plaintiffs' Fourth Set of Interrogatories to Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.; (2) Plaintiffs' First Set of Requests for Admission to Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. (Nos. 1-11); and (3) Plaintiffs' Notice of Deposition to Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 08/05/2024) (3) |
| Aug 5, 2024 | 164 | NOTICE OF SERVICE of (1) Plaintiffs' Fourth Set of Interrogatories to Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc.; (2) Plaintiffs' First Set of Requests for Admission to Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (Nos. 1-11); and (3) Plaintiffs' Notice of Deposition to Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 08/05/2024) (3) |
| Aug 2, 2024 | 161 | NOTICE OF SERVICE of Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s First Supplemental Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 13-14) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 08/02/2024) (2) |
| Aug 2, 2024 | 162 | NOTICE OF SERVICE of 1) Notice of Deposition of Plaintiffs' Witness Biliana Veleva-Rotse; 2) Notice of Deposition of Plaintiffs' Witness Brandon Alan Wustman; 3) Notice of Deposition of Plaintiffs' Witness David Lockhart; 4) Notice of Deposition of Plaintiffs' Witness Elfrida Benjamin; 5) Notice of Deposition of Plaintiffs' Witness Evan Katz; 6) Notice of Deposition of Plaintiffs' Witness Hung V. Do; 7) Notice of Deposition of Plaintiffs' Witness Jacqueline Agey; 8) Notice of Deposition of Plaintiffs' Witness Jasmine Rutecki; 9) Notice of Deposition of Plaintiffs' Witness Jeff Castelli; 10) Notice of Deposition of Plaintiffs' Witness Joe Giuliano; 11) Notice of Deposition of Plaintiffs' Witness John Flanagan; 12) Notice of Deposition of Plaintiffs' Witness Julie Yu; 13) Notice of Deposition of Plaintiffs' Witness Ken Valenzano; 14) Notice of Deposition of Plaintiffs' Witness Vivian Kessler; and 15) Notice of Deposition of Plaintiffs' Witness Xiaoyang Wu filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 08/02/2024) (2) |
| Aug 1, 2024 | 158 | STIPULATION TO EXTEND TIME to Answer Defendants' Counterclaims and Defendants' Second Amended Counterclaims to August 8, 2024 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 08/01/2024) (1) |
| Aug 1, 2024 | 159 | STIPULATION and Covenant Not to Sue Regarding U.S. Patent Nos. 9,999,618, 10,792,279, 10,806,727, 10,849,889, 10,849,890, 10,874,657, 11,278,536, 11,278,537, 11,278,538, 11,278,539, 11,278,540, 11,304,940, 11,357,761, 11,357,762, 11,357,763, 11,357,764, 11,357,765, 11,357,784, 11,376,244, 11,389,436, 11,389,437, 11,426,396, 11,458,128, 11,666,564, and 11,826,360 by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 08/01/2024) (7) |
| Jul 18, 2024 | 157 | NOTICE OF SERVICE of (1) Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Second Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-11); and (2) Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 13-14) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 07/18/2024) (3) |
| Jul 15, 2024 | 156 | NOTICE OF SERVICE of Defendants' Supplemental Preliminary Disclosure of Prior Art filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 07/15/2024) (3) |
| Jul 11, 2024 | 154 | ANSWER to Amended Complaint, re: 145 Amended Complaint, (Third Amended Complaint) by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 07/11/2024) (30) |
| Jul 11, 2024 | 155 | ANSWER to Amended Complaint, re: 144 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc..(DiBenedetto, Emily) (Entered: 07/11/2024) (30) |
| Jul 1, 2024 | 152 | NOTICE OF SERVICE of Teva Defendants' Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 13 - 14) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 07/01/2024) (2) |
| Jul 1, 2024 | 153 | STIPULATION TO EXTEND TIME for Aurobindo Defendants' Responses to Plaintiffs' Third Set of Interrogatories to July 17, 2024 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 07/01/2024) (3) |
| Jun 27, 2024 | 150 | STIPULATION TO EXTEND TIME for Defendants to Answer Amended Complaints to July 11, 2024 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/27/2024) (2) |
| Jun 27, 2024 | 151 | STIPULATION TO EXTEND TIME for Plaintiffs to assert the non-OB Listed Patents to until seven (7) days after the Federal Circuit issues an opinion in the matter of Celanese Intl Corp. v. ITC, Appeal No. 2022-1827 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/27/2024) (2) |
| Jun 25, 2024 | 147 | Pro Hac Vice Fee - Credit Card Payment received for Nicholas Groombridge, Jennifer H. Wu, Josephine Young, Jennifer Rea Deneault, and Peter Sandel. ( Payment of $ 250, receipt number ADEDC-4437396).(Stover, Chad) (Entered: 06/25/2024) (0) |
| Jun 25, 2024 | 148 | Pro Hac Vice Fee - Credit Card Payment received for Naz Wehrli, Stephen Accursio Maniscalco, Allison C. Penfield, and Kyle N. Bersani. ( Payment of $ 200, receipt number ADEDC-4437410).(Stover, Chad) (Entered: 06/25/2024) (0) |
| Jun 25, 2024 | 149 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas Groombridge, Jennifer H. Wu, Josephine Young, Jennifer Rea Deneault, Peter Sandel, Naz Wehrli, Stephen Accursio Maniscalco, Allison C. Penfield and Kyle N. Bersani - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/25/2024) (12) |
| Jun 20, 2024 | 146 | STIPULATION TO EXTEND TIME for Plaintiffs to Assert the Non-OB Listed Patents to June 27, 2024 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/20/2024) (3) |
| Jun 13, 2024 | 144 | Complaint* (1) |
| Jun 13, 2024 | 145 | Complaint* (1) |
| Jun 13, 2024 | 142 | STIPULATION TO EXTEND TIME for Plaintiffs to assert the non-OB Listed Patents to June 20, 2024 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/13/2024) (3) |
| Jun 13, 2024 | 143 | NOTICE OF SERVICE of Plaintiffs' Second Supplemental Preliminary Disclosure of Asserted Claims filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 06/13/2024) (3) |
| May 31, 2024 | 141 | NOTICE OF SERVICE of Plaintiffs' Third Set of Interrogatories to Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. and Plaintiffs' Third Set of Interrogatories to Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 05/31/2024) (3) |
| May 20, 2024 | 140 | NOTICE OF SERVICE of Plaintiffs' Supplemental Response (No. 9) and Second Supplemental Response (No. 7) to Defendants' First Set of Interrogatories filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 05/20/2024) (3) |
| May 14, 2024 | 139 | NOTICE OF SERVICE of Plaintiffs' Supplemental Preliminary Disclosure of Asserted Claims (directed to Teva) and Plaintiffs' Supplemental Preliminary Disclosure of Asserted Claims (directed to defendants) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 05/14/2024) (3) |
| Apr 12, 2024 | 137 | SO ORDERED D.I. 136 Stipulation To Amend Scheduling Order filed by Amicus Therapeutics, Inc., Amicus Therapeutics US, LLC. Reset Scheduling Order Deadlines: A Pretrial Conference is set for 6/6/2025 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke, Fact Discovery completed by 9/5/2024, Opening Expert Reports due by 10/31/2024, Rebuttal Expert Reports due by 12/19/2024, Expert Discovery due by 3/20/2025, Daubert Motions due by 4/24/2025, A 5-day Bench Trial is set for 6/23/2025 at 09:00 AM in Courtroom 2A before Judge Christopher J. Burke. Please see stipulation for further details and deadlines. Signed by Judge Christopher J. Burke on 4/12/2024. (dlb) Modified on 6/6/2024 to correct date of pretrial conference as set forth in stipulation (smg). (Entered: 04/12/2024) (4) |
| Apr 12, 2024 | 138 | ORAL ORDER: The Court today has entered the parties' proposed stipulated orders regarding the case and its schedule. (D.I. 135; D.I. 136) It notes that the number of patents at issue in this case is large, and the parties' stipulation at D.I. 135 is long and a bit confusing. The Court's interest is in making sure that we move the case forward in a fair and expeditious manner such that we can have a trial on a manageable number of patents/issues/claims in June 2025. To the extent that, in the future, the parties believe that the Court should take further action to promote trial efficiency, they may feel free to reach out to the Court by way of motion or otherwise in that regard. Ordered by Judge Christopher J. Burke on 4/12/2024. (dlb) (Entered: 04/12/2024) (0) |
| Apr 11, 2024 | 135 | STIPULATION and [Proposed] Order Regarding Patents Asserted After June 8, 2023 by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 04/11/2024) (9) |
| Apr 11, 2024 | 136 | STIPULATION and [Proposed] Order to Amend Scheduling Order re SO ORDERED, 25 Proposed Order, SO ORDERED,, Set Scheduling Order Deadlines, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 04/11/2024) (4) |
| Mar 27, 2024 | 134 | STIPULATION TO EXTEND TIME to Amend or Supplement the Pleadings, Including by Joining Additional Parties and/or Asserting Additional Patents to June 13, 2024 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 03/27/2024) (2) |
| Mar 20, 2024 | 132 | NOTICE of Change of Address by Chad S.C. Stover (Stover, Chad) (Entered: 03/20/2024) (2) |
| Mar 20, 2024 | 133 | NOTICE OF SERVICE of Plaintiffs' Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc.'s Supplemental Responses to Defendants' First Set of Interrogatories (Nos. 3-8, 10-13) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 03/20/2024) (3) |
| Feb 20, 2024 | 131 | NOTICE OF SERVICE of 1) Response to Defendants' Second Set of Joint Requests for Production to Plaintiffs (Nos. 86-90) and 2) Response to Defendants' Second Set of Interrogatories (No. 16) filed by Amicus Therapeutics US, LLC.(Stover, Chad) (Entered: 02/20/2024) (3) |
| Feb 6, 2024 | 130 | Pro Hac Vice Fee - Credit Card Payment received for Ashley Graham. ( re 129 MOTION for Pro Hac Vice Appearance of Attorney Ashley Graham )( Payment of $ 50, receipt number ADEDC-4331449).(Hoeschen, Nathan) (Entered: 02/06/2024) (0) |
| Jan 25, 2024 | 129 | MOTION for Pro Hac Vice Appearance of Attorney Ashley Graham - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) (Entered: 01/25/2024) (3) |
| Jan 19, 2024 | 127 | NOTICE OF SERVICE of Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s First Supplemental Responses and Objections to Plaintiffs First Set of Interrogatories (Nos. 8, 9, and 11) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 01/19/2024) (2) |
| Jan 19, 2024 | 128 | NOTICE OF SERVICE of 1. Defendants' Second Set of Joint Request for Production to Plaintiffs (Nos. 86 - 90) 2. Defendants' Second Set of Interrogatories (No. 16) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 01/19/2024) (2) |
| Jan 5, 2024 | 126 | ORAL ORDER: The Court, having reviewed the parties' Joint Motion for Teleconference to Resolve Discovery Dispute ("Motion"), (D.I. 93), and the briefing related thereto, (D.I. 96; D.I. 99; D.I. 103), hereby ORDERS that Plaintiffs' Motion be GRANTED in the manner that follows and for the reasons that follow: (1) With regard to interrogatory ("ROG") 8, Plaintiffs are asking for both a further narrative answer to the ROG and for a listing of the five persons called for by the ROG. (D.I. 96 at 1; D.I. 103 at 1) The ROG (which asks about Defendants Aurobindo Pharma Ltd.'s and Aurobindo Pharma USA, Inc.'s ("Defendants") knowledge of the asserted patents) is relevant at least to induced infringement, and persons with knowledge of this subject matter are likely to have relevant information about this and other key aspects of the case.; (2) With regard to ROG 9, Plaintiffs are asking for a listing of "each person" who participated in preparing the notice letters at issue (not just a listing of the names of the entities where those persons work). (D.I. 96 at 2; D.I. 103 at 1) The Court agrees with Plaintiffs that these persons (particularly those who work at Defendant) are likely to have relevant knowledge about key non-infringement and invalidity defenses in the case.; and (3) With regard to ROG 11, by the time of their reply brief, Plaintiffs were simply asking for a listing of the five persons most knowledgeable about the subject (the subject being Defendants' request for samples of a drug product from Plaintiffs). (D.I. 103 at 1) The Court agrees with Plaintiffs that the persons involved in that request are likely to have knowledge of relevant information in the case, such as information about certain objective indicia of non-obviousness. (Id.; see also D.I. 122); (4) Therefore, by no later than January 15, 2024, Defendants shall supplement their responses to ROGs 8, 9 and 11 by providing the sought-after information referenced above.; and (5) The videoconference scheduled for January 8, 2024 is CANCELED. Ordered by Judge Christopher J. Burke on 1/5/2024. (dlb) (Entered: 01/05/2024) (0) |
| Jan 2, 2024 | 125 | STIPULATION and [Proposed] Order re HEK assay amenable mutation claim terms by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 01/02/2024) (5) |
| Dec 28, 2023 | 124 | NOTICE OF SERVICE of (1) Teva Defendants' Supplemental Paragraph 3 Disclosures and (2) Teva Defendants' Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-4, 7-9 and 11) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 12/28/2023) (2) |
| Dec 22, 2023 | 123 | ANSWER to Amended Complaint, re: 56 Amended Complaint, by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 12/22/2023) (30) |
| Dec 18, 2023 | 122 | ORAL ORDER: The Court, having reviewed the parties' Joint Motion for Teleconference to Resolve Discovery Dispute ("Motion"), (D.I. 86), and the briefing related thereto, (D.I. 95; D.I. 97; D.I. 100), hereby ORDERS that Plaintiffs' requests be GRANTED-in-part and DENIED-in-part in the manner and for the reasons that follow: (1) Plaintiffs' requests for relief facially seek an order compelling Defendants Teva Pharms. USA, Inc. and Teva Pharms. Inc. (collectively, "Teva") to: (a) fully respond to Plaintiffs' interrogatories ("ROGs") 1-4, 7-9 and 11; (b) supplement their paragraph 3 disclosures to identify additional custodians; and (c) eventually collect and produce documents from those custodians at some point in the future. (D.I. 95 at 1) But in their opening letter brief, (D.I. 95), Plaintiffs only provide argument that would support an order requiring Teva to: (a) respond to the portion of the ROGs that ask for disclosure of the relevant number of persons most knowledgeable or most involved in the subject matter of the particular ROG at issue (assuming such people exist); and (b) update their paragraph 3 disclosures as to such people (again, assuming such people exist). (Put differently, Plaintiffs never really address why any further substantive responses to those ROGs are required, nor why the answers that Teva provided to some of the ROGs were otherwise incomplete. This dispute, in the end, is all about getting Teva to list the names of persons with knowledge.).; (2) As to this more focused type of relief, Plaintiffs have demonstrated that individuals who would have knowledge about subject matter discussed in the ROGs may also likely have information related to certain relevant aspects of the claims and defenses at issue in the case, particularly as to certain objective indicia of nonobviousness (i.e., failure of others, long-felt need, unexpected results, and commercial success), see ABS Glob., Inc. v. Inguran, LLC, 14-cv-503-wmc, 2019 WL 3812520, at *12 (W.D. Wis. Aug. 14, 2019); Abraxis Biosci. v. Actavis LLC, 16-1925 (JMV), 2017 WL 9808442, at *2-3 (D.N.J. Sept. 12, 2017); Allergan, Inc. v. Teva Pharm. USA, Inc., No. 2:15-CV-1455-WCB, 2017 WL 1319555, at *4 (E.D. Tex. Apr. 10, 2017); In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Pat. Litig., Civ. No. 09-MD-2118-SLR, 2010 WL 3766530, at *2 (D. Del. Sept. 21, 2010); cf. Knoll Pharm. Co. v. Teva Pharms. USA, Inc., 367 F.3d 1381, 1385 (Fed. Cir. 2004), and certain aspects of the induced infringement claims. (D.I. 95 at 2-4; D.I. 100 at 1) The ROGs, one way or the other, ask for identification of people who know something about Teva's ANDA and ANDA product; such people are the people who also are most likely to know something about these relevant aspects of the claims and defenses at issue.; (3) Teva never states that there are no additional custodians who could be listed. Occasionally, Teva suggests that such persons' knowledge might be cumulative. (D.I. 97 at 3) But such a suggestion is merely attorney argument at this stage and should not bar relevant discovery.; (4) Therefore, by no later than December 28, 2023, Teva shall supplement their responses to ROGs 1-4, 7-9, and 11 to list the persons requested (if such persons exist) and shall supplement their paragraph 3 disclosures (the extent there are such additional persons to list). If Teva does identify such persons, and if Plaintiffs seek discovery on certain topics from such persons and Teva refuses, the parties can bring any crystallized dispute on that front to the Court at a later date (though the Court hopes they will be able to work things out).; and (5) The videoconference scheduled for December 18, 2023 to hear argument on the Motion is CANCELED. Ordered by Judge Christopher J. Burke on 12/18/2023. (dlb) (Entered: 12/18/2023) (0) |
| Dec 15, 2023 | 121 | STIPULATION TO EXTEND TIME Plaintiffs' to Serve Their Opening Claim Construction Brief is Extended from December 21, 2023 to January 4, 2024, and the Deadline for Defendants' to Serve Their Answering Claim Construction Brief is Extended from February 1, 2024 to February 15, 2024 to - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 12/15/2023) (2) |
| Dec 12, 2023 | 120 | ORAL ORDER: The Court, having reviewed Plaintiffs' December 8, 2023 letter, (D.I. 118), hereby ORDERS that Plaintiffs' request is DENIED, and the discovery dispute videoconference scheduled for December 18, 2023 will solely be between Plaintiffs and Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. The discovery dispute videoconference scheduled for January 8, 2024 between Plaintiffs and Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. will remain a separate hearing (unless it is cancelled beforehand because the Court has resolved the issue on the papers). Ordered by Judge Christopher J. Burke on 12/12/2023. (dlb) (Entered: 12/12/2023) (0) |
| Dec 11, 2023 | 119 | Letter to The Honorable Christopher J. Burke from Nathan R. Hoeschen regarding Defendants' position in support of Defendants' Motion to Defer Claim Construction - re 111 Oral Order,,,,. (Hoeschen, Nathan) (Entered: 12/11/2023) (3) |
| Dec 8, 2023 | 118 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding consolidated teleconference re: discovery disputes - re 94 Order Setting Teleconference,,,,,,, 87 Order Setting Videoconference,,,,,,,. (Stover, Chad) (Entered: 12/08/2023) (1) |
| Dec 4, 2023 | 116 | ORAL ORDER: The Court, having considered Plaintiffs' Notice Regarding Intent to Have Newer Attorney Argue Motion, (D.I. 114), and pursuant to the Court's Standing Order Regarding Courtroom Opportunities for Newer Attorneys, hereby ORDERS that the Court will ensure that sufficient time is permitted for argument regarding the motion, and will permit experienced counsel to provide assistance when appropriate. Ordered by Judge Christopher J. Burke on 12/4/2023. (dlb) (Entered: 12/04/2023) (0) |
| Dec 4, 2023 | 117 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding Amicus' position re: argument on the disputed claim term - re 111 Oral Order,,,,. (Stover, Chad) (Entered: 12/04/2023) (3) |
| Dec 1, 2023 | 114 | NOTICE of Intent to Have Newer Attorney Argue Motion by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. re 66 MOTION to Strike // Renewed Motion to Strike Defendants' Affirmative Defense Nos. 2, 5, and Defendants' Improper Denials (Stover, Chad) (Entered: 12/01/2023) (2) |
| Dec 1, 2023 | 115 | MOTION for Pro Hac Vice Appearance of Attorney George J. Barry III - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 12/01/2023) (4) |
| Nov 30, 2023 | 112 | [SEALED] STIPULATION and [Proposed] Order to Stay Litigation With Respect to Lupin, Ltd and Lupin Pharmaceuticals, Inc. by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Attachments: # 1 Certificate of Service)(Stover, Chad) (Entered: 11/30/2023) (0) |
| Nov 30, 2023 | 113 | REDACTED VERSION of (112 in 1:22-cv-01461-CJB, 20 in 1:23-cv-00964-CJB) Stipulation, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 11/30/2023) (9) |
| Nov 27, 2023 | 111 | ORAL ORDER: The Court, having reviewed the parties' claim construction-related motions, (D.I. 108; D.I. 109), and the discussion in the parties' Joint Claim Construction Chart, (D.I. 107), notes that it would be helpful to get a little more information on the parties' positions before making a decision on whether to go forward with the scheduled May 2024 Markman hearing, and therefore ORDERS as follows: (1) By no later than December 4, 2023, Plaintiffs may file a letter, not to exceed two single-spaced pages, providing more information on their position as to why it would maximize efficiency and be best for the case to hear argument about the disputed claim term set out in D.I. 107 at the May 2024 Markman hearing (including a discussion about what is different about this term as compared to the additional claim terms on which the parties have jointly proposed to defer argument until later in the case); and (2) by no later than December 11, 2023, Defendants may file a letter, not to exceed two single-spaced pages, providing more information on their position to the contrary. Ordered by Judge Christopher J. Burke on 11/27/2023. (dlb) (Entered: 11/27/2023) (0) |
| Nov 20, 2023 | 104 | NOTICE OF SERVICE of Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s [HIGHLY CONFIDENTIAL] Objections and Responses to Plaintiffs' Second Set of Interrogatories (No. 12) filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Bilson, David) (Entered: 11/20/2023) (2) |
| Nov 20, 2023 | 105 | NOTICE OF SERVICE of Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Responses and Objections to Plaintiffs' Second Set of Interrogatories (No. 12) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 11/20/2023) (2) |
| Nov 20, 2023 | 106 | STIPULATION and [Proposed] Order re Claim Terms by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 11/20/2023) (5) |
| Nov 20, 2023 | 107 | CLAIM Construction Chart by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 11/20/2023) (5) |
| Nov 20, 2023 | 108 | MOTION for Claim Construction re 65 STIPULATION TO EXTEND TIME to file contentions to various dates, 107 Claim Construction Chart, 29 Scheduling Order,,, - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 11/20/2023) (2) |
| Nov 20, 2023 | 109 | MOTION to Defer Claim Construction re 107 Claim Construction Chart - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 11/20/2023) (3) |
| Nov 20, 2023 | 110 | NOTICE OF SERVICE of Teva Defendants' Responses and Objections to Plaintiff's Second Set of Interrogatories (No. 12) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 11/20/2023) (2) |
| Nov 17, 2023 | 102 | MOTION for Pro Hac Vice Appearance of Attorney Kevin Boyle - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 11/17/2023) (3) |
| Nov 17, 2023 | 103 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding discovery dispute - re 99 Letter. (Stover, Chad) (Entered: 11/17/2023) (2) |
| Nov 16, 2023 | 101 | STIPULATION TO EXTEND TIME for the parties to file a Joint Claim Construction Chart to November 20, 2023 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 11/16/2023) (2) |
| Nov 14, 2023 | 100 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding discovery dispute - re 97 Letter. (Attachments: # 1 Exhibit A)(Stover, Chad) (Entered: 11/14/2023) (0) |
| Nov 10, 2023 | 99 | Letter to The Honorable Christopher J. Burke from R Touhey Myer regarding regarding Discovery Dispute - re 96 Letter. (Myer, R.) (Entered: 11/10/2023) (4) |
| Nov 9, 2023 | 98 | NOTICE OF SERVICE of Plaintiffs' Disclosure of Claim Terms with Proposed Construction and Intrinsic Evidence filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 11/09/2023) (3) |
| Nov 7, 2023 | 97 | Letter to The Honorable Christopher J. Burke from Nathan R. Hoeschen regarding In Opposition to Plaintiff's Motion to Compel. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Hoeschen, Nathan) (Entered: 11/07/2023) (0) |
| Nov 3, 2023 | 96 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding discovery dispute - re 94 Order Setting Teleconference,,,,,,,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Stover, Chad) (Entered: 11/03/2023) (0) |
| Oct 31, 2023 | 95 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding discovery dispute - re 87 Order Setting Videoconference,,,,,,,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Stover, Chad) (Entered: 10/31/2023) (0) |
| Oct 30, 2023 | 94 | ORAL ORDER: The Court, having reviewed the parties' Joint Motion for Teleconference to Resolve Discovery Dispute, (D.I. 93), hereby ORDERS as follows: (1) A discovery dispute videoconference using the Microsoft Teams platform is set for January 8, 2024 at 2:00 p.m. before Judge Christopher J. Burke.; (2) By November 3, 2023, Plaintiffs shall file with the Court a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the issues in dispute and their position on those issues. By November 10, 2023, Defendants shall file with the Court a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the reasons for their opposition. By no later than November 17, 2023, Plaintiffs shall file with the Court a reply letter brief, not to exceed one (1) single-spaced page, in no less than 12-point font.; (3) By no later than December 29, 2023, the parties shall send an e-mail to the Court's Courtroom Deputy, Ms. Benyo, indicating the names and e-mail addresses of all individuals who will participate in the videoconference.; (4) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; (5) The Court may choose to resolve the dispute prior to the videoconference and will, in that event, cancel the videoconference (however, if any party advises the Court in advance that a newer attorney will argue the dispute, see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf, then the Court will go forward with the conference). Ordered by Judge Christopher J. Burke on 10/30/2023. (dlb) (Entered: 10/30/2023) (0) |
| Oct 26, 2023 | 88 | NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms for Construction filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 10/26/2023) (2) |
| Oct 26, 2023 | 89 | NOTICE OF SERVICE of Defendants' Proposed Terms for Construction filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 10/26/2023) (2) |
| Oct 26, 2023 | 90 | NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms for Construction (served on Lupin) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 10/26/2023) (2) |
| Oct 26, 2023 | 91 | NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms for Construction (served on Aurobindo) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 10/26/2023) (2) |
| Oct 26, 2023 | 92 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding the parties' request to schedule a discovery teleconference. (Stover, Chad) (Entered: 10/26/2023) (2) |
| Oct 26, 2023 | 93 | Joint MOTION for Discovery // Joint Motion for Teleconference to Resolve Discovery Dispute - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 10/26/2023) (3) |
| Oct 24, 2023 | 87 | ORAL ORDER: The Court, having reviewed the parties' joint Motion for Teleconference to Resolve Discovery Dispute, (D.I. 86), hereby ORDERS as follows: (1) A discovery dispute videoconference using the Microsoft Teams platform is set for December 18, 2023 at 3:30 p.m. before Judge Christopher J. Burke.; (2) By October 31, 2023, Plaintiffs shall file with the Court a letter, not to exceed four (4) single-spaced pages, in no less than 12-point font, outlining the issues in dispute and their position on those issues. By November 7, 2023, Defendants shall file with the Court a letter, not to exceed four (4) single-spaced pages, in no less than 12-point font, outlining the reasons for their opposition. By no later than November 14, 2023, Plaintiffs shall file with the Court a reply letter brief, not to exceed one (1) single-spaced page, in no less than 12-point font.; (3) By no later than December 8, 2023, the parties shall send an e-mail to the Court's Courtroom Deputy, Ms. Benyo, indicating the names and e-mail addresses of all individuals who will participate in the videoconference.; (4) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; (5) The Court may choose to resolve the dispute prior to the videoconference and will, in that event, cancel the videoconference (however, if any party advises the Court in advance that a newer attorney will argue the dispute, see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf, then the Court will go forward with the conference).. Signed by Judge Christopher J. Burke on 10/24/2023. (dlb) (Entered: 10/24/2023) (0) |
| Oct 20, 2023 | 85 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding discovery disputes. (Stover, Chad) (Entered: 10/20/2023) (2) |
| Oct 20, 2023 | 86 | Joint MOTION for Discovery // Joint Motion for Teleconference to Resolve Discovery Dispute - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 10/20/2023) (3) |
| Oct 19, 2023 | 82 | NOTICE OF SERVICE of 1) Plaintiffs' Second Set of Interrogatories to Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. and 2) Plaintiffs' Preliminary Infringement Contentions filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 10/19/2023) (2) |
| Oct 19, 2023 | 83 | NOTICE OF SERVICE of 1) Plaintiffs' Second Set of Interrogatories to Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc. and 2) Plaintiffs' Preliminary Infringement Contentions filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 10/19/2023) (2) |
| Oct 19, 2023 | 84 | NOTICE OF SERVICE of 1) Plaintiffs' Second Set of Interrogatories to Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. and 2) Plaintiffs' Preliminary Infringement Contentions filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 10/19/2023) (2) |
| Oct 17, 2023 | 81 | ORAL ORDER: The Court hereby ORDERS that a videoconference to hear argument on Plaintiffs' Renewed Motion to Strike ("Motion"), (D.I. 66), is set for December 11, 2023 at 1:00 p.m. before Judge Christopher J. Burke via the Microsoft Teams platform. By no later than December 1, 2023, the parties shall send an e-mail to the Court's Courtroom Deputy, Ms. Benyo, indicating the names and e-mail addresses of all individuals who will participate in the hearing. The Court may choose to resolve the Motion prior to the videoconference and will, in that event, cancel the videoconference (however, if any party advises the Court in advance that a newer attorney will argue the dispute, see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf, then the Court will go forward with the conference). Ordered by Judge Christopher J. Burke on 10/17/2023. (dlb) (Entered: 10/17/2023) (0) |
| Oct 6, 2023 | 80 | Official Transcript of Hearing held on 8/7/23 Court Reporter Deanna Warner, Email: deanna_warner@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 10/27/2023. Redacted Transcript Deadline set for 11/6/2023. Release of Transcript Restriction set for 1/4/2024. (Warner, Deanna) (Entered: 10/06/2023) (56) |
| Sep 29, 2023 | 79 | NOTICE OF SERVICE of Lupin Limited and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Amended Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures and Lupin Limited and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Amended Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Bilson, David) (Entered: 09/29/2023) (3) |
| Sep 13, 2023 | 78 | REQUEST for Oral Argument by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. re 66 MOTION to Strike // Renewed Motion to Strike Defendants' Affirmative Defense Nos. 2, 5, and Defendants' Improper Denials. (Stover, Chad) (Entered: 09/13/2023) (2) |
| Sep 12, 2023 | 76 | PROPOSED ORDER // [Proposed] Protective Order by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 09/12/2023) (30) |
| Sep 12, 2023 | 77 | PROTECTIVE ORDER. Signed by Judge Christopher J. Burke on 9/12/2023. (dlb) (Entered: 09/12/2023) (30) |
| Sep 11, 2023 | 75 | NOTICE OF SERVICE of Defendants Initial Invalidity Contentions Pursuant to the Default Standard for Discovery filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Phillips, John) (Entered: 09/11/2023) (2) |
| Sep 6, 2023 | 74 | REPLY BRIEF re 66 MOTION to Strike // Renewed Motion to Strike Defendants' Affirmative Defense Nos. 2, 5, and Defendants' Improper Denials filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 09/06/2023) (16) |
| Aug 30, 2023 | 73 | ANSWERING BRIEF in Opposition re 66 MOTION to Strike // Renewed Motion to Strike Defendants' Affirmative Defense Nos. 2, 5, and Defendants' Improper Denials filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..Reply Brief due date per Local Rules is 9/6/2023. (Myer, R.) (Entered: 08/30/2023) (11) |
| Aug 29, 2023 | 72 | NOTICE OF SERVICE of (i) Response to Defendants' First Set of Interrogatories (Nos. 1-15) and (ii) Response to Defendants' First Set of Joint Requests for Production to Plaintiffs (Nos. 1-85) filed by Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 08/29/2023) (3) |
| Aug 24, 2023 | 69 | NOTICE OF SERVICE of Lupin Limited and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Initial Noninfringement Contentions filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Bilson, David) (Entered: 08/24/2023) (2) |
| Aug 24, 2023 | 70 | NOTICE OF SERVICE of Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Non-Infringement Contentions and Appendices A-L filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 08/24/2023) (2) |
| Aug 24, 2023 | 71 | NOTICE OF SERVICE of 1) Teva's Initial Non-Infringement Contentions 2) Teva's Initial Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 08/24/2023) (2) |
| Aug 17, 2023 | 68 | MEMORANDUM ORDER regarding D.I. 47 Joint MOTION for Teleconference to Resolve Protective Order Dispute filed by Lupin Ltd., Lupin Pharmaceuticals, Inc.. Signed by Judge Christopher J. Burke on 8/17/2023. (dlb) (Entered: 08/17/2023) (9) |
| Aug 16, 2023 | 66 | MOTION to Strike // Renewed Motion to Strike Defendants' Affirmative Defense Nos. 2, 5, and Defendants' Improper Denials - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Attachments: # 1 Text of Proposed Order)(Stover, Chad) (Entered: 08/16/2023) (0) |
| Aug 16, 2023 | 67 | OPENING BRIEF in Support re 66 MOTION to Strike // Renewed Motion to Strike Defendants' Affirmative Defense Nos. 2, 5, and Defendants' Improper Denials filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..Answering Brief/Response due date per Local Rules is 8/30/2023. (Stover, Chad) (Entered: 08/16/2023) (18) |
| Aug 9, 2023 | 65 | STIPULATION TO EXTEND TIME to file contentions to various dates - filed by Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Bilson, David) (Entered: 08/09/2023) (2) |
| Aug 8, 2023 | 64 | NOTICE OF SERVICE of Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s First Supplemental Responses and Objections to Plaintiffs First Set of Interrogatories (Nos. 1-11) and Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Incs First Supplemental Responses and Objections to Plaintiffs First Set of Requests for Production of Documents and Things (Nos. 1-38) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 08/08/2023) (2) |
| Jul 28, 2023 | 63 | NOTICE OF SERVICE of Defendants' First Set of Interrogatories (Nos. 1-15) and Defendants' First Set of Joint Requests for Production to Plaintiffs (Nos. 1-85) filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Bilson, David) (Entered: 07/28/2023) (3) |
| Jul 26, 2023 | 62 | ANSWER to Amended Complaint, re: 56 Amended Complaint, by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 07/26/2023) (30) |
| Jul 24, 2023 | 61 | NOTICE requesting Clerk to remove Tyree Petty-Williams as co-counsel.. (Hoeschen, Nathan) (Entered: 07/24/2023) (1) |
| Jul 17, 2023 | 59 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding Protective Order - re 55 Letter. (Stover, Chad) (Entered: 07/17/2023) (3) |
| Jul 17, 2023 | 60 | Letter to The Honorable Christopher J. Burke from John C. Phillips, Jr. regarding Defendants responsive letter regarding protective order dispute - re 54 Letter,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Phillips, John) (Entered: 07/17/2023) (0) |
| Jul 13, 2023 | 57 | ANSWER to 50 Answer to Amended Complaint, Counterclaim by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 07/13/2023) (30) |
| Jul 13, 2023 | 58 | ANSWER to 48 Answer to Amended Complaint,, Counterclaim, by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) (Entered: 07/13/2023) (30) |
| Jul 12, 2023 | 56 | Amended Complaint* (1) |
| Jul 10, 2023 | 54 | Letter to The Honorable Christopher J. Burke from Chad S.C. Stover regarding protective order dispute - re 52 Oral Order,,,,,,,, Order Setting Videoconference,,,,,,,. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A - [Proposed] Protective Order)(Stover, Chad) (Entered: 07/10/2023) (0) |
| Jul 10, 2023 | 55 | Letter to The Honorable Christopher J. Burke from John C. Phillips, Jr. regarding Protective Order Dispute - re 52 Oral Order,,,,,,,, Order Setting Videoconference,,,,,,,. (Attachments: # 1 Exhibits A-H)(Phillips, John) (Entered: 07/10/2023) (0) |
| Jul 7, 2023 | 53 | MOTION for Pro Hac Vice Appearance of Attorney Claire Fundakowski - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Keller, Karen) (Entered: 07/07/2023) (3) |
| Jun 27, 2023 | 52 | ORAL ORDER Setting Videoconference: The Court has reviewed the parties' June 20, 2023 letter requesting a teleconference regarding one dispute relating to a proposed protective order. It hereby ORDERS that the procedures for resolving a protective order dispute set out in the Scheduling Order will be modified as follows with regard to this dispute: (1) A protective order dispute videoconference using the Microsoft Teams platform is set for 8/7/2023 at 09:30 AM before Judge Christopher J. Burke.; (2) By no later than July 10, 2023, each party shall file with the Court a letter, not to exceed two pages, in no less than 12-point font, outlining the issue in dispute and its position on that issue. By no later than July 17, 2023, each party may file a letter, not to exceed two pages, in no less than 12-point font, outlining that party's response to the opposing party's initial letter.; (3) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; (4) By no later than July 17, 2023, the parties shall send an e-mail to the Court's Courtroom Deputy, Ms. Benyo, indicating the names and e-mail addresses of all individuals who will participate in the hearing.; and (5) The Court may choose to resolve the disputes prior to the videoconference and will, in that event, cancel the conference (however, if any party advises the Court in advance that a newer attorney will argue the dispute, see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf, then the Court will go forward with the conference). Ordered by Judge Christopher J. Burke on 6/27/2023. (mlc) (Entered: 06/27/2023) (0) |
| Jun 26, 2023 | 51 | NOTICE OF SERVICE of (1) Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-11); and (2) Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc's Responses and Objections to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-38) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 06/26/2023) (2) |
| Jun 22, 2023 | 48 | ANSWER to Amended Complaint, re: 37 Amended Complaint, Affirmative Defenses, COUNTERCLAIM against Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) (Entered: 06/22/2023) (30) |
| Jun 22, 2023 | 49 | STIPULATION and [Proposed] Order Dismissing Springcare USA dba Spring Bio Solution by Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John) (Entered: 06/22/2023) (3) |
| Jun 22, 2023 | 50 | ANSWER to Amended Complaint, re: 38 Amended Complaint, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Lupin Pharmaceuticals, Inc., Lupin Ltd..(Phillips, John) (Entered: 06/22/2023) (30) |
| Jun 20, 2023 | 42 | ORDER FOR DISCOVERY, INCLUDING DISCOVERY OF ELECTRONICALLY STORED INFORMATION (ESI) filed by Amicus Therapeutics, Inc., Amicus Therapeutics US, LLC. Signed by Judge Christopher J. Burke on 6/20/2023. (dlb) (Entered: 06/20/2023) (9) |
| Jun 20, 2023 | 43 | ORAL ORDER: The Court, having reviewed the case history in light of the parties June 6, 2023 consent, hereby ORDERS as follows: (1) the Markman hearing, pretrial conference, and trial will remain as scheduled, except they will be held in Courtroom 2A before Judge Christopher J. Burke.; and (2) The procedures for resolving a discovery dispute set out in the Scheduling Order, (D.I. 29 at 14-16), will be modified as follows: Should counsel find, after good faith efforts including verbal communication among Delaware and Lead Counsel for all parties to the dispute, that they are unable to resolve a discovery matter, the parties involved in the discovery matter dispute shall submit a joint letter with the text set out in the Court's standard Rule 16 Scheduling Order for Non-Patent cases, which can be found in the "Forms" tab of Magistrate Judge Burke's page on the District Court's website. The moving party (i.e., the party seeking relief from the Court) should also file a Motion For Teleconference To Resolve Discovery Dispute. The suggested text for this motion can be found in the same Forms tab, under the heading "Discovery Matters -- Motion to Resolve Discovery Dispute." The Court will thereafter set a discovery dispute telephone conference and briefing schedule. Ordered by Judge Christopher J. Burke on 6/20/2023. (dlb) (Entered: 06/20/2023) (0) |
| Jun 20, 2023 | 44 | NOTICE OF SERVICE of Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-11) and Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s Objections and Responses to Plaintiffs' First Set of Requests for Production (Nos. 1-38) filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Bilson, David) (Entered: 06/20/2023) (3) |
| Jun 20, 2023 | 45 | NOTICE OF SERVICE of 1. Teva Defendants' Responses and Objections to Plaintiff's Request for Production of Documents 2. Teva Defendants' Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1 - 11) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 06/20/2023) (2) |
| Jun 20, 2023 | 46 | Letter to The Honorable Christopher J. Burke from David A. Bilson regarding requesting protective order dispute conference. (Bilson, David) (Entered: 06/20/2023) (2) |
| Jun 20, 2023 | 47 | Joint MOTION for Teleconference to Resolve Protective Order Dispute - filed by Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Bilson, David) (Entered: 06/20/2023) (2) |
| Jun 15, 2023 | 40 | PROPOSED ORDER for Discovery, Including Discovery of Electronically Stored Information ("ESI") by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/15/2023) (9) |
| Jun 15, 2023 | 41 | STIPULATION TO EXTEND TIME to File a Proposed Protective Order to June 16, 2023 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/15/2023) (3) |
| Jun 8, 2023 | 38 | Amended Complaint* (1) |
| Jun 8, 2023 | 37 | Amended Complaint* (1) |
| Jun 8, 2023 | 39 | NOTICE OF SERVICE of (1) Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Initial Disclosures Pursuant to F.R.C.P. 26(a)(1); and (2) Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.'s Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 06/08/2023) (2) |
